Yuki Tobisawa
Overview
Explore the profile of Yuki Tobisawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishiwaki T, Kawase K, Nishino Y, Matsuoka K, Ihara T, Makabe S, et al.
Int Urol Nephrol
. 2025 Feb;
PMID: 39956876
Purpose: To examine daytime voiding patterns in patients with nocturnal polyuria (NP) and identify a novel predictive indicator based on voiding frequency ratios. Methods: A retrospective analysis of 875 patients...
2.
Taniguchi T, Iinuma K, Kawada K, Ishida T, Takagi K, Tomioka M, et al.
Curr Oncol
. 2024 Dec;
31(12):7914-7923.
PMID: 39727706
A combination of nivolumab and ipilimumab (NIVO + IPI) is the only approved combination of two immune checkpoint inhibitors for metastatic or advanced renal cell carcinoma (mRCC). Inadequate evidence of...
3.
Kawase M, Nakane K, Iinuma K, Kawase K, Taniguchi T, Tomioka M, et al.
J Clin Med
. 2024 Sep;
13(18).
PMID: 39337047
The overall survival (OS) of patients with prostate cancer (PCa) who receive locally definitive therapy is generally better than that of patients who do not receive definitive therapy. There is...
4.
Nakane K, Kawase M, Kato D, Iinuma K, Kawase K, Takeuchi S, et al.
Transl Cancer Res
. 2024 Aug;
13(7):3889-3897.
PMID: 39145084
Background And Objective: Prostate cancer (PCa) is the most common cancer in men. High-risk PCa is associated with an increased risk of PCa-related death. The combined use of androgen deprivation...
5.
Nakane K, Taniguchi K, Nezasa M, Enomoto T, Yamada T, Tomioka-Inagawa R, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123376
Randomized phase III trial results have demonstrated enfortumab vedotin (EV), an antibody-drug conjugate (ADC) consisting of an anti-Nectin-4 human IgG1 monoclonal antibody and monomethyl auristatin E, is a useful treatment...
6.
Kumada N, Iinuma K, Kubota Y, Takagi K, Nakano M, Ishida T, et al.
Diseases
. 2024 Jun;
12(6).
PMID: 38920554
In this study, we aimed to determine the utility of cytoreductive nephrectomy (CN) in real-world clinical practice and investigate whether CN contributes to improved oncological outcomes in patients with metastatic...
7.
Tomioka M, Nakane K, Kawase M, Iinuma K, Kato D, Kawase K, et al.
Curr Oncol
. 2024 May;
31(5):2846-2855.
PMID: 38785497
Accurate diagnosis of the localization of prostate cancer (PCa) on magnetic resonance imaging (MRI) remains a challenge. We aimed to assess discrepancy between the location of PCa pathologically diagnosed using...
8.
Ito H, Nakane K, Hagiwara N, Kawase M, Kato D, Iinuma K, et al.
Curr Oncol
. 2024 May;
31(5):2758-2768.
PMID: 38785490
We aimed to investigate the differences in renal function between patients who underwent single inner-layer renorrhaphy (SILR) or double-layer renorrhaphy (DLR) among those with renal tumors who underwent robot-assisted partial...
9.
Kobori Y, Tachizaki M, Imaizumi T, Tanaka Y, Seya K, Miki Y, et al.
Mol Biol Rep
. 2024 Mar;
51(1):417.
PMID: 38483660
Background: Bronchial epithelial cells are at the front line of viral infections. Toll-like receptor 3 (TLR3) cascade causes the expression of interferon (IFN)-β and IFN-stimulated genes (ISGs), which in turn...
10.
Kawase M, Kato D, Tobisawa Y, Iinuma K, Nakane K, Koie T
Int J Urol
. 2024 Mar;
31(7):826-828.
PMID: 38454625
No abstract available.